⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RPRX News
Royalty Pharma plc Class A Ordinary Shares
Immuno-Oncology Drugs Market Projected to Reach US$ 185.69 Billion by 2035 | Astute Analytica
globenewswire.com
VRTX
MRK
BMY
GILD
JNJ
AZN
NVS
REGN
AMGN
PFE
BIIB
ISRG
MDLZ
IMCR
CRSP
EDIT
NCLH
ACRS
ALNY
INCY
ABBV
LULU
EXAS
RDVY
ONCY
GENM
DTIL
XAIR
CGEN
ADPT
ATRC
CODX
CORT
CRBU
CTAS
CYTK
DASH
DECK
DOCU
EBAY
ELAN
ENPH
EPAM
FIVN
FORM
FTNT
GDRX
GEHC
GNTX
GOOS
GRMN
GTLB
HGV
HLT
HOLX
HON
HPE
HPQ
HRB
HSIC
HWM
IDXX
ILMN
INSM
INTC
INTU
IRTC
ITRI
IVZ
JBL
JEF
JHG
JLL
JPM
KDP
KHC
KODK
LAKE
LCID
LRCX
LSCC
LYFT
MCHP
MELI
MGM
MKTX
MLCO
MNST
MRVL
MTCH
MU
NDSN
NEO
NET
NFLX
NKE
NOC
NOW
NRG
NTAP
NTES
NVDA
NXPI
ODFL
OMC
ON
ORCL
ORLY
OSK
OTIS
OXY
PANW
PAYX
PCAR
PCG
PDD
PEP
PGR
PH
PHG
PII
PKX
PLAB
PLD
PLUG
PM
PNW
POOL
POST
PPG
PPL
PRGS
PRGO
PRLB
PRO
PRTA
PSFE
PSNY
PTC
PVH
QCOM
QGEN
QRVO
RBLX
RCL
RDNT
REI
REIT
RF
RGEN
RIVN
RL
RMBS
RMD
ROBT
ROKU
ROST
RPRX
RS
RSG
RSP
RVSN
RYAAY
S
SABR
SAN
SAVA
SBAC
SBRA
SBUX
SCHD
SCL
SD
SE
SEDG
SEE
SEIC
SELF
SEM
SIRI
SJM
SKX
SLB
SLGN
SMCI
SMLR
SNBR
SNOW
SNPS
SO
SONO
SPCE
SPGI
SPNS
SQM
SRPT
SSNC
ST
STAG
STLD
STNG
STOK
STX
SUN
SWKS
SYK
SYY
T
TAL
TAN
TCOM
TDOC
TECK
TEF
TEK
TEL
TER
TFX
TGT
TGTX
THC
THO
TIGR
TITN
TJX
TLRY
TMO
TMUS
TNDM
TNET
TOL
TOPS
TORO
TPH
TPL
TQQQ
TR
TRC
TRIP
TRMB
TRMK
TRN
TRP
TRT
TRVG
TS
TSCO
TSE
TSLA
TSN
TT
TTC
TTD
TTI
TTNP
TTWO
TU
TUSK
TV
TVC
TVE
TW
TWLO
TX
TXN
TXRH
TXT
TYL
U
UAL
UBER
UDR
UEC
UHAL
ULTA
UMC
UMH
UNFI
UNH
UNIT
UNM
UPST
URBN
USA
USFD
USNA
USPH
UTHR
V
VRSK
VTR
VTRS
VZ
W
WAB
WDC
WEC
WELL
WEN
WERN
WEX
WFC
WGO
WHD
WHR
WIA
WMB
WMT
WNS
WPC
WRB
WST
WTAI
WTFC
WTS
WU
WY
WYNN
XBIT
XCUR
XENE
XFLT
XGN
XHR
XLP
XOM
XPO
XRAY
XRT
XTLB
XXII
XYL
YETI
YMM
YPF
YUM
Z
ZBRA
ZCMD
ZIM
ZION
ZKIN
ZNTL
ZTO
ZTS
ZYME
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
globenewswire.com
RPRX
CytoAgents Appoints Dr. Johannes Wolff as Chief Medical Officer and Michael Howell as Chief Scientific Officer
businesswire.com
RPRX
ABBV
NVS
ZURA
INCY
AZN
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
globenewswire.com
RPRX
NUVL
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
prnewswire.com
ONCY
IMRX
TNGX
MRNA
RPRX
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
globenewswire.com
RPRX
DNLI
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
globenewswire.com
DNLI
RPRX
Royalty Pharma to Present at Upcoming Investor Conferences
globenewswire.com
RPRX
Royalty Pharma Reports Third Quarter 2025 Results
globenewswire.com
RPRX
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
globenewswire.com
RPRX